CDK2AP2P3: A Potential Drug Target and Biomarker (G401525)

Target Name: CDK2AP2P3

NCBI ID: G401525

CDK2AP2P3

Other Name(s): Cyclin-dependent kinase 2 associated protein 2 pseudogene 3 | cyclin dependent kinase 2 associated protein 2 pseudogene 3

CDK2AP2P3: A Potential Drug Target and Biomarker

Cyclin-dependent kinase (CDK) 2 is a key regulator of cell cycle progression, and its dysfunction has been implicated in various diseases, including cancer. The CDK2-associated protein 2 (CDK2AP2) has been identified as a potential drug target and biomarker for various diseases, including cancer. CDK2AP2P3, a pseudogene found in humans, is a promising candidate for drug targeting.

CDK2AP2P3: A Putative Drug Target

CDK2 is a protein that plays a critical role in regulating cell cycle progression by activating the G1-phase and inhibiting the S-phase. CDK2AP2 is a 21-kDa protein that is expressed in various tissues and cells, including brain, heart, and cancer cells. It is a key regulator of the G1-phase and is involved in the regulation of cell cycle progression, apoptosis, and autophagy.

Studies have shown that CDK2AP2 is involved in various cellular processes, including cell growth, apoptosis, and cell cycle regulation. It has been shown to play a critical role in the regulation of cell cycle progression, and its dysfunction has been implicated in various diseases, including cancer.

CDK2AP2P3 has been shown to be a potential drug target by various methods, including its expression in various tissues and its involvement in cellular processes. For instance, studies have shown that overexpression of CDK2AP2 can lead to the development of various cancer types, including breast, ovarian, and prostate cancer. Additionally, it has been shown to be involved in the regulation of cell apoptosis, which is a critical mechanism that helps cells eliminate damaged or dysfunctional cells.

CDK2AP2P3: A Potential Biomarker

CDK2AP2P3 has also been shown to be a potential biomarker for various diseases, including cancer. Its involvement in the regulation of cell apoptosis makes it an attractive candidate for use as a biomarker for cancer.

Studies have shown that CDK2AP2 is involved in the regulation of cell apoptosis, which is a critical mechanism that helps cells eliminate damaged or dysfunctional cells. CDK2AP2 has been shown to play a critical role in the regulation of cell apoptosis by activating the B-cell lymphoma 1 (Bcl-2) gene.

CDK2AP2P3 has also been shown to be involved in the regulation of cancer cell migration. Cancer cells have been shown to have the ability to migrate throughout the body and are responsible for the development of various types of cancer. CDK2AP2 has been shown to play a critical role in the regulation of cancer cell migration by regulating the activity of the protein, called FAK (focal adhesion kinase).

Conclusion

CDK2AP2P3 is a pseudogene that has been shown to play a critical role in various cellular processes, including cell growth, apoptosis, and cell cycle regulation. Its involvement in these processes makes it a potential drug target and biomarker for various diseases, including cancer. Further studies are needed to fully understand the role of CDK2AP2P3 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Cyclin Dependent Kinase 2 Associated Protein 2 Pseudogene 3

The "CDK2AP2P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK2AP2P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets